GlassScriptPhysician profile
Chad S Hendrickson
NPI 1780665075
$4,438.60
in general payments reported to CMS, 2019-2025
21 companies · $1,954 in 2025
The $1,954 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $99.99 · 2021: $13.20 · 2022: $101 · 2023: $571 · 2024: $1,700 · 2025: $1,954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,224.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $985.39 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $697.94 | 2023-2025 | |
| Leo Pharma INC. | $446.68 | 2024-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $432.94 | 2020-2025 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $351.06 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $307.17 | 2024-2025 | Dupixent |
| Ucb, INC. | $306.19 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $151.97 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $114.32 | 2024-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.46 | 2023-2025 | Spevigo, Cyltezo |
| Pfizer INC. | $95.92 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $83.74 | 2024-2025 | |
| Dermavant Sciences, INC. | $83.61 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $73.99 | 2023-2025 | Zoryve |
| Organogenesis INC. | $54.40 | 2024 | Puraply Am |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $46.47 | 2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.91 | 2024 | Arazlo, Cabtreo, Jublia |
| Biofrontera INC. | $21.05 | 2025 | Ameluz |
| Journey Medical Corporation | $19.88 | 2025 | |
| Amgen INC. | $15.52 | 2023 | Otezla |
| Galderma Laboratories, L.P. | $13.99 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Hendrickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.